Media coverage about KaloBios Pharmaceuticals (NASDAQ:KBIO) has trended positive on Friday, Alpha One Sentiment Analysis reports. The research firm, a subsidiary of Accern, scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. KaloBios Pharmaceuticals earned a media sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned media coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.
KaloBios Pharmaceuticals (NASDAQ:KBIO) traded down 5.242% during midday trading on Friday, hitting $2.464. The stock had a trading volume of 3,714 shares. KaloBios Pharmaceuticals has a 52-week low of $1.90 and a 52-week high of $6.00. The company’s 50 day moving average price is $2.53 and its 200-day moving average price is $3.12. The stock’s market cap is $36.90 million.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Mideast Time and is owned by of Mideast Time. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.mideasttime.com/kalobios-pharmaceuticals-kbio-receives-coverage-optimism-rating-of-0-31/1708111.html.
About KaloBios Pharmaceuticals
KaloBios Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.
Receive News & Ratings for KaloBios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KaloBios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.